Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746162 | 1.00 | KCNH2 (0.62) | KCNH2POLA1 | |
| SCHEMBL6749887 | 0.93 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6749882 | 0.93 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6746088 | 0.93 | KCNH2 (0.59) | KCNH2POLA1 | |
| SCHEMBL6746095 | 0.93 | KCNH2 (0.59) | KCNH2POLA1 | |
| SCHEMBL6686542 | 0.92 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL6686536 | 0.92 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL6681328 | 0.92 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL6681321 | 0.92 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL6749818 | 0.90 | KCNH2 (0.69) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-6831081-B2 | Herpes virus including simplex types 1 and 2, varicella zoster, human cytomegalovirus, Epstein-Barr and human 6, 7 and 8 | PHARMACIA & UPJOHN | 2004-12-14 | — | — | US | disclosed |
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, MAVS | KCNH2 1376/4885POLA1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.